TY - JOUR
T1 - Framework nucleic acids as programmable carrier for transdermal drug delivery
AU - Wiraja, Christian
AU - Zhu, Ying
AU - Lio, Daniel Chin Shiuan
AU - Yeo, David C.
AU - Xie, Mo
AU - Fang, Weina
AU - Li, Qian
AU - Zheng, Mengjia
AU - Van Steensel, Maurice
AU - Wang, Lihua
AU - Fan, Chunhai
AU - Xu, Chenjie
PY - 2019
Y1 - 2019
N2 - DNA nanostructures are promising drug carriers with their intrinsic biocompatibility, uniformity and versatility. However, rapid serum disintegration leads to low bioavailability at targeted sites following systemic administration, hindering their biomedical applications. Here we demonstrate transdermal delivery of framework nucleic acids (FNAs) through topical applications. By designing FNAs with distinct shapes and sizes, we interrogate their penetration on mice and human skin explant. Skin histology reveals size-dependent penetration, with FNAs ≤75 nm effectively reaching dermis layer. 17 nm-tetrahedral FNAs show greatest penetration to 350 µm from skin periphery. Importantly, structural integrity is maintained during the skin penetration. Employing a mouse melanoma model, topical application of doxorubicin-loaded FNAs accommodates ≥2-fold improvement in drug accumulation and tumor inhibition relative to topically-applied free doxorubicin, or doxorubicin loaded in liposomes and polymeric nanoparticles. Programmable penetration with minimal systemic biodistribution underlines FNA potential as localized transdermal drug delivery carriers.
AB - DNA nanostructures are promising drug carriers with their intrinsic biocompatibility, uniformity and versatility. However, rapid serum disintegration leads to low bioavailability at targeted sites following systemic administration, hindering their biomedical applications. Here we demonstrate transdermal delivery of framework nucleic acids (FNAs) through topical applications. By designing FNAs with distinct shapes and sizes, we interrogate their penetration on mice and human skin explant. Skin histology reveals size-dependent penetration, with FNAs ≤75 nm effectively reaching dermis layer. 17 nm-tetrahedral FNAs show greatest penetration to 350 µm from skin periphery. Importantly, structural integrity is maintained during the skin penetration. Employing a mouse melanoma model, topical application of doxorubicin-loaded FNAs accommodates ≥2-fold improvement in drug accumulation and tumor inhibition relative to topically-applied free doxorubicin, or doxorubicin loaded in liposomes and polymeric nanoparticles. Programmable penetration with minimal systemic biodistribution underlines FNA potential as localized transdermal drug delivery carriers.
UR - http://www.scopus.com/inward/record.url?scp=85062613507&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85062613507&origin=recordpage
U2 - 10.1038/s41467-019-09029-9
DO - 10.1038/s41467-019-09029-9
M3 - RGC 21 - Publication in refereed journal
C2 - 30850596
SN - 2041-1723
VL - 10
JO - Nature Communications
JF - Nature Communications
M1 - 1147
ER -